EWTX241018P12500
- 0.05
- 0.000.00%
Edgewise Therapeutics Newsroom
Edgewise Therapeutics Put Volume Heavy and Directionally Bearish
Edgewise Therapeutics(EWTX.US) Officer Sells US$3.57 Million in Common Stock
Edgewise Therapeutics CFO Sells Over $3.5 Million in Company Stock
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $33
Form 144 | Edgewise Therapeutics(EWTX.US) Officer Proposes to Sell 3.57 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 20, $Edgewise Therapeutics(EWTX.US)$ Officer ROBERT MICHAEL CARRUTHERS intends to sell 125.09K shares of its common stock on Sep 20, with a total market value of
Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $44
Edgewise Therapeutics Analyst Ratings
Express News | Edgewise Therapeutics Inc : RBC Raises Target Price to $42 From $32
Small U.S. Stocks Close Up; Edgewise Therapeutics Climbs Highest
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Leerink Partners Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $42
Buy Rating Affirmed on Edgewise Therapeutics' EDG-7500 for HCM Treatment Due to Promising Efficacy and Safety Profile
Edgewise Therapeutics Is Maintained at Buy by Truist Securities
Top Midday Gainers
Edgewise Therapeutics Up 47%, Announces Topline Phase 1 and 2 Data for Heart Disease Treatment
Edgewise Therapeutics Up Nearly 47%, On Pace for Record Percent Increase -- Data Talk
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings
Wedbush Adjusts Edgewise Therapeutics Price Target to $44 From $31, Maintains Outperform Rating
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $33